EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours

Folia Neuropathologica

Volumn 48, Issue 4, 2010, Pages 238-245

  Izycka Swieszewska, Ewa ^a   Brzeskwiniewicz, Magdalena ^a   Wozniak, Agnieszka ^b   Drozynska, Elzbieta ^a   Grajkowska, Wieslawa ^c,d   Perek, Danuta ^c   Balcerska, Anna ^a   Klepacka, Teresa ^e   Limon, Janusz ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^d MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^e INSTITUTE OF MOTHER AND CHILD   (Poland)

Author keywords

EGFR; Mutation; Neuroblastoma; PI3K AKT mTOR pathway; PIK3CA; Protein expression; PTEN

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; VASCULOTROPIN RECEPTOR;

ARTICLE; CHILD; CONTROLLED STUDY; DNA POLYMORPHISM; EXON; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; NEUROBLASTOMA; PRESCHOOL CHILD; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

EID: 78650490962     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Boller D, Schramm A, Doepfner K, Shalaby T, Bueren A, Eggert A, Grotzer M, Arcaro A. Targeting the phosphoinositide 3-kinase isoform p110 delta impairs growth and survival in neuroblastoma cells. Clin Cancer Res 2008;14:1172-1181.
2. Cheng C, Fan Q, Weiss W. PI3K signaling in glioma-animal models and therapeutic challanges. Brain Pathology 2009;19:112-120.
3. Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay K. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27:289-297.
4. Dam V, Morgan B, Mazanek P, Hogarty M. Mutations in PIK3CA are infrequent in neuroblastoma. BMC Cancer 2006;6:177-187.
5. Gallia G, Rand V, Siu I, Eberhart C, James D, Marie S, Shinjo S, Carlotti C, Caballero O, Simpson A, Brock M, Massion P, Carson B, Riggins G. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res 2006;4:709-714.
6. Izycka-Swieszewska E, Wozniak A, Kot J, Grajkowska W, Balcerska A, Perek D, Baginska-Dembowska B, Klepacka T, Drozynska E. Prognostic significance of HER2 expression in neuroblastic tumors. Modern Pathol 2010;23:1261-1268.
7. Jakacki R, Hamilton M, Gilbertson R, Blaney S, Tersak J, Krailo M, Ingle A, Voss S, Dancey J, Adamson P. Pediatric phase I and pharmacokinetic study of Erlotinib followed by the combinantion of Erlotinib and Temozolomid: a children's oncology group phase I consortium study. J Clin Oncol 2008;26:4921-4927.
8. Karakas B, Bachman K, Park B. Mutation of the PIK3CA oncogene in human cancers. British J Cancer 2006;94:455-459.
9. Kok K, Geering B, Vanhaesebroeck B. Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci 2009;34:115-127.
10. Lachyankar M, Sultana N, Schonoff C, Mitra P, Poluha W, Lambert S, Quesenberry P, Litofsky N, Recht L, Nabi R, Miller S, Ohta S, Neel B, Ross A. A role for nuclear PTEN in neuronal differentiation. J Neurosci 2000;20:1404-1413.
11. Ligresti G, Militello L, Steelman L, Cavallaro A, Basile F, Nicoletti F, Stivala F, Mc Cubrey J, Libra M. PIK3CA mutations in human solid tumors. Cell Cycle 2009;8:1352-1358.
12. Maris J, Hogarty M, Bagatell R, Cohn S. Neuroblastoma. Lancet 2007;369:2106-2120.
13. Markman B, Atzori F, Perez-Garcia J, Tabernero J, Baselga J. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 2010;21:683-691.
14. Moritake H, Horii Y, Kuroda H, Sugimoto T. Analysis of PTEN/MMAC1 alteration in neuroblastoma. Cancer Genet Cytogenet 2001;125:151-155.
15. Mosse Y, Laudenslager M, Longo L. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-935.
16. Munoz J, Lazcoz P, Inda M, Nistal M, Pestana A, Encio I, Castresana J. Homozygous deletion and expression of PTEN and DMBT1 in human primary neuroblastoma and cell lines. Int J Cancer 2004;109:673-679.
17. Musatov S, Roberts J, Brooks A, Pena J, Betchen S, Pfaff D, Kaplitt M. Inhibition of neuronal phenotype by PTEN in PC12 cells. PNAS 2004;101:3627-3631.
18. Nicholas M, Lukas R, Jafri N, Faoro L, Salgia R. Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 2006;12:7261-7270.
19. Opel D, Poremba C, Simon T, Debatin K, Fulda S. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 2007;67:735-745.
20. Qiao J, Kang J, Cree J, Evers M, Chung D. Gastrin-Realising Peptide-Induced down-regulation of tumor suppressor protein PTEN in neuroblastomas. Ann Surg 2005;241:684-692.
21. Qiu W, Schönleben F, Li X, Ho D, Close L, Manolidis S, Bennett B, Su G. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2006;12:1441-1446.
22. Richards KN, Zweidler-McKay PA, Van Roy N, Speleman F, Trevino J, Zage P, Hughes D. Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. Cancer 2010;116:3233-3243.
23. Saal L, Johansson P, Holm K, Gruvberger-Saal S, She Q, Maurer M, Koujak S, Ferrando A, Malmstrom P, Memeo L, Isola J, Bendahl P, Rosen N, Hibshoosh H, Ringner M, Borg A, Parsons R. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. PNAS 2007;104:7564-7569.
24. Samuels Y, Wang Z, Bardelli A, Siliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell S, Riggins G, Willson J, Markowitz S, Kinzler K, Vogelstein B, Velculescu V. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554. (Pubitemid 38541907)
25. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954-2963.
26. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipitis M. EGFR/KRAS/BRAF mutations in primary lung adenocarcinoma and corresponding locoregional lymph node metastases. Clin Cancer Res 2009;15:4554-4560.
27. Stefanowicz J, Izycka-Swieszewska E, Drozynska E, Pienczk J, Polczynska K, Czauderna P, Sierota D, Bien E, Stachowicz-Stencel T, Kosiak W, Balcerska A. Neuroblastoma and opsoclonusmyoclonusataxia syndrome - clinical and pathological characteristics. Folia Neuropathol 2008;46:176-185.
28. Stiles B. Phosphatase and tensin homologue deleted on chromosome 10: Extending its PTENtacles. Int J Biochem Cell Biol 2009;41:757-761.
29. Van Roy N, De Preter K, Hoebeeck J, Van Maerken T, Pattyn F, Mestdagh P, Vermeulen J, Vandesompele J, Speleman F. The emerging molecular pathogenesis of neuroblastoma: implications form improved risk assessment and targeted therapy. Genome Med 2009;1:74.
30. Włodarski P, Baszczyk A, Grajkowska W, Roszkowski M, Jozwiak S. Implication of active Erk in the classic type of human medulloblastoma. Folia Neuropathol 2008;46:117-122.
31. Zawrocki A, Biernat W. Epidermal growth factor in glioblastoma. Folia Neuropathol 2005;43:123-132.